Companies › NervGen Pharma
1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NVG-291 Peptide therapeutic designed to promote nervous system repair and functional recovery | – | Phase 3 | Chronic Spinal Cord Injury | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07799532 | NVG-291 | Phase 3 | Chronic Spinal Cord Injury | Neurology | Jul 2027 |
Cash of 22m CAD on 2025-12-31; operating cash outflow about 20m CAD a year; runway about 14 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Immunic Alpha Cognition Satellos Bioscience Coya Therapeutics PepGen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.